Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 10Active not recruiting 3Terminated 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Tumor-Agnostic 1

Conditions

Non-small Cell Lung Cancer Metastatic 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 27Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × necitumumab × Thoracic × Clear all
NCT03054038 2022-04-14

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Vanderbilt-Ingram Cancer Center

Phase 1 Terminated
22 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02443337 2020-12-09

A Study of LY3023414 and Necitumumab in Squamous Lung Cancer

Eli Lilly and Company

Phase 2 Terminated
31 enrolled 14 charts
Thoracic

Non-small Cell Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡